Heggie, R., Jaiswal, N. , McCartney, E. , Moss, J., Menne, T., Jones, B., Boyd, K. , Soulis, E., Hawkins, N. and Wu, O. (2024) Central venous access devices for the delivery of systemic anticancer therapy: an economic evaluation. Value in Health, 27(1), pp. 7-14. (doi: 10.1016/j.jval.2023.09.2996) (PMID:37844662)

Morga, A., Latimer, N. R., Scott, M., Hawkins, N. , Schlichting, M. and Wang, J. (2023) Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework?: insights and perspectives from the national institute for health and care excellence and institut für qualität und wirtschaftlichkeit im gesundheitswesen on the international council for harmonisation of technical requirements for pharmaceuticals for human use E9 (R1) addendum. Value in Health, 26(2), pp. 234-242. (doi: 10.1016/j.jval.2022.08.008) (PMID:36150999)

ten Ham, R. M.T., Frederix, G. W.J., Wu, O. , Goettsch, W., Leufkens, H. G.M., Klungel, O. H. and Hoekman, J. (2022) Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands, and England. Value in Health, 25(3), pp. 390-399. (doi: 10.1016/j.jval.2021.09.012) (PMID:35227451)

Due, O. T., Thakkinstian, A., Thavorncharoensap, M., Sobhonslidsuk, A., Wu, O. , Phuong, N. K. and Chaikledkaew, U. (2020) Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam. Value in Health, 23(9), pp. 1180-1190. (doi: 10.1016/j.jval.2020.03.018) (PMID:32940236) (PMCID:PMC7491253)

Anopa, Y., Macpherson, L. and McIntosh, E. (2020) Systematic review of economic evaluations of primary caries prevention in 2- to 5-year-old preschool children. Value in Health, 23(8), pp. 1109-1118. (doi: 10.1016/j.jval.2020.04.1823)

Wiksten, A., Hawkins, N. , Piepho, H.-P. and Gsteiger, S. (2020) Non-proportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value in Health, 23(7), pp. 918-927. (doi: 10.1016/j.jval.2020.03.010) (PMID:32762994)

Allanson, P. F., Brown, E. A., Kopasker, D. and Kwiatkowski, A. (2020) An investigation of the stability of patients’ treatment preferences over the course of a clinical trial. Value in Health, 23(6), pp. 775-781. (doi: 10.1016/j.jval.2019.12.011) (PMID:32540236)

Fawsitt, C. G. et al. (2020) Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chronic hepatitis C virus. Value in Health, 23(2), pp. 180-190. (doi: 10.1016/j.jval.2019.08.012) (PMID:32113623) (PMCID:PMC7057278)

Fawsitt, C. G. et al. (2019) A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic hepatitis C virus. Value in Health, 22(6), pp. 693-703. (doi: 10.1016/j.jval.2018.12.011) (PMID:31198187) (PMCID:PMC6588649)

Pennington, M., Grieve, R., Van der Meulen, J. and Hawkins, N. (2018) The value of external data in the extrapolation of survival data: a study using the NJR data set. Value in Health, 21(7), pp. 822-829. (doi: 10.1016/j.jval.2017.12.023) (PMID:30005754)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021) (PMID:29241890)

Griffin, E. A. et al. (2017) Cost-effectiveness analysis of natriuretic peptide testing and specialist management in patients with suspected acute heart failure. Value in Health, 20(8), pp. 1025-1033. (doi: 10.1016/j.jval.2017.05.007) (PMID:28964433)

Hoogendoorn, M., Feenstra, T. L., Asukai, Y., Briggs, A. H. , Hansen, R. N., Leidl, R., Risebrough, N., Samyshkin, Y., Wacker, M. and Rutten-van Mölken, M. P.M.H. (2017) External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value in Health, 20(3), pp. 397-403. (doi: 10.1016/j.jval.2016.10.016) (PMID:28292484)

Ciani, O., Buyse, M., Drummond, M., Rasi, G., Saad, E. D. and Taylor, R. S. (2017) Time to review the role of surrogate endpoints in health policy: state of the art and the way forward. Value in Health, 20(3), pp. 487-495. (doi: 10.1016/j.jval.2016.10.011) (PMID:28292495)

Wilkinson, T. et al. (2016) The international decision support initiative reference case for economic evaluation: an aid to thought. Value in Health, 19(8), pp. 921-928. (doi: 10.1016/j.jval.2016.04.015) (PMID:27987641)

Wolowacz, S. E., Briggs, A. , Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A. and Norman, R. (2016) Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), pp. 704-719. (doi: 10.1016/j.jval.2016.06.001) (PMID:27712695)

Hoogendoorn, M. et al. (2016) Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19(6), pp. 800-810. (doi: 10.1016/j.jval.2016.04.002) (PMID:27712708)

Walker, A. (2016) Challenges in using MCDA for reimbursement decisions on new medicines? Value in Health, 19(2), pp. 123-124. (doi: 10.1016/j.jval.2016.02.001) (PMID:27021744)

Becker, U., Briggs, A. H. , Moreno, S. G., Ray, J. A., Ngo, P. and Samanta, K. (2016) Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value in Health, 19(4), pp. 374-382. (doi: 10.1016/j.jval.2015.12.018) (PMID:27325329)

Belozeroff, V., Chertow, G. M., Graham, C. N., Dehmel, B., Parfrey, P. S. and Briggs, A. H. (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value in Health, 18(8), pp. 1079-1087. (doi: 10.1016/j.jval.2015.08.007) (PMID:26686794)

McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)

Wailoo, A., Hernández, M., Philips, C., Brophy, S. and Siebert, S. (2015) Modeling health state utility values in Ankylosing Spondylitis: comparisons of direct and indirect methods. Value in Health, 18(4), pp. 425-431. (doi: 10.1016/j.jval.2015.02.016) (PMID:26091596)

Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A. and Sullivan, S. D. (2015) Cost-effectiveness analysis alongside clinical trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 18(2), pp. 161-172. (doi: 10.1016/j.jval.2015.02.001) (PMID:25773551)

Halfpenny, N.J.A., Quigley, J.M. , Donatti, C. and Hawkins, N.S. (2014) Non-treatment specific parameter value estimates: relationship between BMI and utility. Value in Health, 17(7), A544. (doi: 10.1016/j.jval.2014.08.1757) (PMID:27201756)

Quigley, J.M. , Thompson, J.C., Halfpenny, N., Scott, D.A. and Hawkins, N.S. (2014) Riding the E-Publication wave. Value in Health, 17(7), A545. (doi: 10.1016/j.jval.2014.08.1763) (PMID:27201761)

Hoogendoorn, M. et al. (2014) Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value in Health, 17(5), pp. 525-536. (doi: 10.1016/j.jval.2014.03.1721)

Laws, A., Kendall, R. and Hawkins, N. (2014) A comparison of national guidelines for network meta-analysis. Value in Health, 17(5), pp. 642-654. (doi: 10.1016/j.jval.2014.06.001) (PMID:25128059)

Levy, A. R., Briggs, A. H. , Johnston, K., MacLean, J. R., Yuan, Y., L’Italien, G. J., Kalsekar, A. and Schnitzler, M. A. (2014) Projecting long-term graft and patient survival after transplantation. Value in Health, 17(2), pp. 254-260. (doi: 10.1016/j.jval.2014.01.001)

Caro, J.J., Eddy, D. M., Kan, H., Kaltz, C., Patel, B., Eldessouki, R. and Briggs, A. H. (2014) Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health, 17(2), pp. 174-182. (doi: 10.1016/j.jval.2014.01.003)

Ciani, O., Hoyle, M., Pavey, T., Cooper, C., Garside, R., Rudin, C. and Taylor, R. (2013) Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value in Health, 16(6), pp. 1081-1090. (doi: 10.1016/j.jval.2013.07.004) (PMID:24041359)

Jaime Caro, J., Eddy, D.M., Hollingworth, W., Tsevat, J., McDonald, K.M., Wong, J.B., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2013) ISPOR-SMDM task force’s recommendations for good modeling practices—reply to letter to the editor by Corro Ramos. Value in Health, 16(6), p. 1108. (doi: 10.1016/j.jval.2013.06.016)

Garrison, L.P., Towse, A., Briggs, A. , de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P. and Sleeper, M. (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), pp. 703-719. (doi: 10.1016/j.jval.2013.04.011)

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H. , Mauskopf, J. and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 16(2), pp. 231-250. (doi: 10.1016/j.jval.2013.02.002)

Briggs, A.H. , Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J. and Paltiel, A.D. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value in Health, 15(6), pp. 835-842. (doi: 10.1016/j.jval.2012.04.014)

Caro, J.J., Briggs, A.H. , Siebert, U. and Kuntz, K.M. (2012) modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15(6), pp. 796-803. (doi: 10.1016/j.jval.2012.06.012)

Hoaglin, D. C. et al. (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value in Health, 14(4), pp. 429-437. (doi: 10.1016/j.jval.2011.01.011) (PMID:21669367)

Jansen, J. P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N. , Lee, K., Boersma, C., Annemans, L. and Cappelleri, J. C. (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value in Health, 14(4), pp. 417-428. (doi: 10.1016/j.jval.2011.04.002) (PMID:21669366)

Price, M.J., Welton, N.J., Briggs, A.H. and Ades, A.E. (2011) Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. Value in Health, 14(2), pp. 205-218. (doi: 10.1016/j.jval.2010.08.001)

Starkie, H.J., Briggs, A.H. , Chambers, M.G. and Jones, P. (2011) Predicting EQ-5D Values Using the SGRQ. Value in Health, 14(2), pp. 354-360. (doi: 10.1016/j.jval.2010.09.011)

Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)

Woods, B., Veenstra, D. and Hawkins, N. (2011) Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value in Health, 14(8), pp. 989-1001. (doi: 10.1016/j.jval.2011.05.048) (PMID:22152167)

Court, H., Greenland, K. and Margrain, T.H. (2010) Measuring patient anxiety in primary care: Rasch analysis of the 6-item Spielberger state anxiety scale. Value in Health, 13(6), pp. 813-819. (doi: 10.1111/j.1524-4733.2010.00758.x)

Kemler, M. A., Raphael, J. H., Bentley, A. and Taylor, R. S. (2010) The cost-effectiveness of spinal cord stimulation for complex regional pain syndrome. Value in Health, 13(6), pp. 735-742. (doi: 10.1111/j.1524-4733.2010.00744.x) (PMID:20561326)

Szabo, S.M., Levy, A.R., Davis, C., Holyoake, T.L. and Cortes, J. (2010) A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 13(1), pp. 103-111. (doi: 10.1111/j.1524-4733.2009.00573.x)

Briggs, A.H. (2010) Transportability of comparative effectiveness and cost-effectiveness between countries. Value in Health, 13, S22-S25. (doi: 10.1111/j.1524-4733.2010.00751.x)

Taylor, R. S. and Iglesias, C. P. (2009) Assessing the clinical and cost-effectiveness of medical devices and drugs: are they that different? Value in Health, 12(4), pp. 404-406. (doi: 10.1111/j.1524-4733.2008.00476_2.x) (PMID:19138305)

Petrou, S. and McIntosh, E. (2009) Women's preferences for attributes of first-trimester miscarriage management: a stated preference discrete-choice experiment. Value in Health, 12(4), pp. 551-559. (doi: 10.1111/j.1524-4733.2008.00459.x)

Manca, A., Eldabe, S., Buchser, E., Kumar, K. and Taylor, R. S. (2009) Relationship between health-related quality of life, pain, and functional disability in neuropathic pain patients with failed back surgery syndrome. Value in Health, 13(1), pp. 95-102. (doi: 10.1111/j.1524-4733.2009.00588.x) (PMID:19695004)

Hoomans, T., Fenwick, E.A.L., Palmer, S. and Claxton, K. (2009) Value of Information and Value of Implementation: Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer. Value in Health, 12(2), pp. 315-324. (doi: 10.1111/j.1524-4733.2008.00431.x)

Barton, G.R., Briggs, A.H. and Fenwick, E.A.L. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health, 11(5), pp. 886-897. (doi: 10.1111/j.1524-4733.2008.00358.x)

Levy, A.R., Kowdley, K., Iloeje, U.H., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N. and Briggs, A.H. (2008) The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health, 11(3), pp. 527-538. (doi: 10.1111/j.1524-4733.2007.00297.x) (PMID:18179664)

Fenwick, E., Marshall, D.A., Blackhouse, G., Vidaillet, H., Slee, A., Shemanski, L. and Levy, A.R. (2008) Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Value in Health, 11(3), pp. 365-375.

Haefeli, M., Elfering, A., McIntosh, E. , Gray, A., Sukthankar, A. and Boos, N. (2008) A cost-benefit analysis using contingent valuation techniques: a feasibility study in spinal surgery. Value in Health, 11(4), pp. 575-588. (doi: 10.1111/j.1524-4733.2007.00282.x)

Briggs, A.H. , Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D. and Burge, S. (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health, 9(4), pp. 227-235. (doi: 10.1111/j.1524-4733.2006.00106.x)

Briggs, A.H. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2. (doi: 10.1111/j.1524-4733.2005.08101.x)

Ramsey, S. et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health, 8(5), pp. 521-533.

Briggs, A. (2005) Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health, 8(1), pp. 1-2.

Hope, A. and Briggs, A. (2003) Concerns regarding the ISPOR Code of Ethics for Researchers. Value in Health, 7(4), pp. 510-511.

Goeree, R., O'Brien, B., Blackhouse, G., Marshall, J., Briggs, A. and Lad, R. (2002) Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health, 5(4), pp. 312-328.